Trials

  • CERC Trial

    THRIVE

    -

    The THRIVE study is a pivotal, prospective, multicenter, 2:1 randomized, double blind, controlled, study. The objective is to compare the THerapeutic IntravasculaR Ultrasound (TIVUS ) REnal Denervation System vs. Sham for the Adjunctive Treatment of Hypertension.

  • CERC Trial

    TRANSFORM II

    -

    Tranform II is an investigator-drive prospective, multicentric, international, randomized clinical trial. The objective is to observe and evaluate the efficacy of Magic Touch SCB compared to the gold standard treatment for native vessel disease, namely new-generation everolimus-eluting DES. The...

  • CERC Trial

    TRUNC

    -

    Prospective, non-randomized, multi-center study assessing the long term safety and efficacy of the self expandable sirolimus eluting Xposition S stent in the treatment of unprotected left main coronary artery disease. In the treatment of unprotected left main coronary artery (ULMCA) disease...

  • CERC Trial

    Valid-B.Well BP25 Study

    -

    Prospective, single-center, single-arm, open, comparative, validation of a commercialized device, repeated measures accuracy study designed in accordance with the requirements of the ISO 81060-2:2018 AAMI/ESH/ISO Universal Standard for the clinical validation of automated non-invasive...

  • CERC Trial

    VitaFlow LIBERTY Europe

    -

    Aprospective, single-arm, multi-center, observational, post-market clinical follow-up study, aimed to assess the safety and effectiveness/performance of the self-expanding VitaFlow Liberty™ Transcatheter Aortic Valve System in symptomatic patients with severe aortic stenosis in the post market use...

  • CERC Trial

    VITALE

    -

    VITALE is a prospective, single arm clinical investigation evaluating safety and effectiveness/performance of the Microport CardioFlow VitaFlowTM II – Transcatheter Aortic Valve System for the treatment of symptomatic severe aortic stenosis via transcatheter access in increased surgical risk...

  • CERC Trial

    VITUS Post-Market Registry

    -

    VITUS is a Single-arm, Prospective, Open Label, All Comers, Multicenter Registry of paclitaxel drug-coated balloon angioplasty for the treatment of symptomatic peripheral arterial disease to assess the safety and performance of a paclitaxel drug-coated balloon for the treatment of peripheral...

  • CERC Trial

    VIVA

    -

    Evaluation of the Clinical Outcomes of CoreValve in Degenerative Surgical Aortic Bioprosthesis. A Prospective, Observational Post-market Study. This observational study is intended to collect real-world (post-approval use) data regarding the clinical utility and performance of the Medtronic...

  • CERC Trial

    ZENITH

    -

    Evaluation of the Safety and Performance of the Zenith LAA Occlusion System and Procedure for the Mechanical Closure of the Left Atrial Appendage (LAA). Left Atrial Appendage (LAA) closure in patients with non-valvular atrial fibrillation and a maximum LAA ostium width and/or deployed occluder...